
Schlechter discussed the potential advantages of TAC01-HER2 over current standards of care.

Schlechter discussed the potential advantages of TAC01-HER2 over current standards of care.

Schlechter discussed the design of the TACTIC-2 clinical trial for patients with HER2-positive solid tumors.

November 1st 2022